Kymera Therapeutics Announces Pricing of Upsized $602 Million Public Offering

WATERTOWN, Mass., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced the pricing of its underwritten public offering of $602.0 million of shares of its common stock. Kymera is selling 7,000,000 shares of common stock in the offering, which are being sold at a public offering price of $86.00 per share. In addition, Kymera has granted the underwriters a 30-day option to purchase up to an additional 1,050,000 shares of its common stock at the public offering price per share, less underwriting discounts and commissions. The gross proceeds to Kymera from the offering are expected to be approximately $602.0 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Kymera, assuming no exercise of the underwriters’ option to purchase additional shares. All of the securi